openPR Logo
Press release

Inflammatory Bowel Disease Ibd Market 2018-2026 major industry players- Pfizer Inc., Shire Plc., Janssen Biotech, Inc., AbbVie Inc., Allergan plc., Novartis AG

10-12-2018 03:02 PM CET | Health & Medicine

Press release from: Polaris Market Research & Consulting

Inflammatory Bowel Disease Ibd Market

Inflammatory Bowel Disease Ibd Market

The Global Inflammatory Bowel Disease Market Size to gain traction owning to the factors such as increasing population suffering with IBD that is majorly influenced by the changing lifestyle preferences across the globe.

Inflammatory Bowel Disease is the type of gastrointestinal inflammatory disease. This disease causes long term chronic and severe inflammation in the intestinal tract. Similarly, it can be termed as an inflammatory condition to the colon and small intestine. Inflammatory bowel disease (IBD) on the basis of indication is segmented into Crohn’s disease, and ulcerative colitis. Crohn’s disease not only affects the small intestine but also has the ability to affect the mouth, stomach, the anus, and oesophagus. Whereas, ulcerative colitis affects the rectum and the colon. The number of patients suffering from IBD is on rise due to changing lifestyle globally. According to CDC, there are more than 70,000 new cases of IBD every year in North America.

Request to Sample of This Report @ https://www.polarismarketresearch.com/industry-analysis/global-inflammatory-bowel-disease-ibd-market/request-for-free-sample

In the recent years, there are various research studies that have been focusing on the causes of inflammatory bowel disease. The major causes of IBD includes the genetic mutations that are caused in NOD2/CARD15 gene, and virus or bacteria. In general, inflammatory bowel disease (IBD) is majorly caused by immune malfunctioning, in which the immune system attacks the healthy cells in digestive tract. The factors like age, ethnicity, cigarette smoking, intake of non-steroidal anti-inflammatory medications, and family history support the growth of IBD. The common symptoms observed in an individual suffering from IBD are persistent diarrhoea, cramps in abdomen, fever, and occasional rectal bleeding.

The global inflammatory bowel disease is primarily driven by rising prevalence of inflammatory bowel disease globally. Moreover, the rising preference & intake of fast food, and increasing sedentary lifestyle is responsible to promote the growth of this market in the near future. In addition, the stressful life of the people also influences the global market. Similarly, rising government initiatives for analysing the causes and effective new drug development is expected to create further surge in inflammatory bowel disease (IBD) market.

Inflammatory bowel disease is treated with immunomodulators, corticosteroids, aminosalicyclates, and TNF inhibitors. TNF inhibitors are the most preferred drug class for treating IBD. It holds the major market share in the IBD market owning to their effectiveness and awareness for treating IBD. On the other hand, positive approach for using immunotherapies would also spur the market.

Request for an in-depth table of contents for this report @ https://www.polarismarketresearch.com/industry-analysis/global-inflammatory-bowel-disease-ibd-market/speak-to-analyst

Increased prevalence of Ulcerative Colitis and Crohn’s Disease to lead the market growth in North America.

Geographically, the global market to be segmented as North America, Europe, Asia Pacific, Latin America & Middle East and Africa. North America region is expected to dominate this market over the forecast period. North America holds major share owning to the rising number of patients suffering from ulcerative colitis and Crohn’s disease, and changed diet preferences in this region. Moreover, well established healthcare infrastructure by the governments in North America to boom the inflammatory bowel disease market in the near future.

However, Asia Pacific to grow at a faster pace in the forecast period. Higher population in this region, and increased preference for sedentary lifestyle in the developing countries are the major factors that anticipated to govern the growth in Asia Pacific market during upcoming years.

Key players in the global inflammatory bowel disease market are:

• Pfizer Inc.
• Shire Plc.
• Janssen Biotech, Inc.
• AbbVie Inc.
• Allergan plc.
• Novartis AG
• UCB Inc.
• Biogen Inc.
• Valent Pharmaceuticals International, Inc.
• Takeda Pharmaceuticals Company Limited.

Make an Inquiry for purchasing this report @ https://www.polarismarketresearch.com/industry-analysis/global-inflammatory-bowel-disease-ibd-market/inquire-before-buying

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers.

Contact us

Mr. Neel
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980
Email: neel@polarismarketresearch.com
Web: www.polarismarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Inflammatory Bowel Disease Ibd Market 2018-2026 major industry players- Pfizer Inc., Shire Plc., Janssen Biotech, Inc., AbbVie Inc., Allergan plc., Novartis AG here

News-ID: 1300449 • Views:

More Releases from Polaris Market Research & Consulting

Anorexiants Market Expected to Attain US$ 1,403.13 Million by 2032, Maintaining 4.8% Compound Annual Growth Rate During 2024 to 2032
Anorexiants Market Expected to Attain US$ 1,403.13 Million by 2032, Maintaining …
Growing consciousness about the genesis and solutions of obesity, together with the internet's availability to a broader consumer base, is disposed to ignite the acquisition of weight management drugs. Based on drug class analysis, the catecholamine's segment witnesses the highest growth. By region, in 2023, North America dominated the market with the largest share. 𝐆𝐞𝐭 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐚𝐠𝐞𝐬 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.polarismarketresearch.com/industry-analysis/anorexiants-market/request-for-sample 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐀𝐝𝐝𝐫𝐞𝐬𝐬𝐞𝐬: • The global anorexiants market was valued
North America Hearing AID Market size of USD 14.48 Billion in 2032, at a CAGR 6.0% from 2024 to 2032 | PMR
North America Hearing AID Market size of USD 14.48 Billion in 2032, at a CAGR 6. …
Polaris Market Research has recently published its latest research report titled "North America Hearing AID Market by Product (Hearing AID Devices and Hearing Implant), Type (Conductive Hearing Loss and Sensorineural Hearing Loss), Patient, Technology - Forecast to 2032." The study reveals that the market is anticipated to grow at a CAGR of 6.0%, reaching a market size of USD 14.48 billion in 2032 from the value of USD 8.58 billion
Vehicle Armor Materials Market Valuation to Hit US$ 10.10 Billion by 2032, Showing 6.2% CAGR During 2024-2032
Vehicle Armor Materials Market Valuation to Hit US$ 10.10 Billion by 2032, Showi …
Global vehicle armor materials market size and share is currently valued at USD 5.98 billion in 2023 and is anticipated to generate an estimated revenue of USD 10.10 billion by 2032, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 6.2% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2024 - 2032 𝐆𝐚𝐢𝐧 𝐈𝐦𝐦𝐞𝐝𝐢𝐚𝐭𝐞 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐎𝐮𝐫 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:
Buy Now Pay Later Market Hits Milestone - Projected at USD 80.52 Billion By 2032 with a Striking 29.20% CAGR
Buy Now Pay Later Market Hits Milestone - Projected at USD 80.52 Billion By 2032 …
Polaris Market Research's recent research demonstrates that the Buy Now Pay Later Market is expected to witness a steady CAGR of 29.20% during the forecast period. The market was valued at USD 8.05 billion in 2023 and is expected to grow to USD 80.52 billion by 2032. Growth can be linked to clients' strong preference for flexible payment options. 𝐆𝐞𝐭 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐚𝐠𝐞𝐬 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.polarismarketresearch.com/industry-analysis/buy-now-pay-later-market/request-for-sample Buy now, pay later,

All 5 Releases


More Releases for IBD

Canada Inflammatory Bowel Disease (IBD) Market Size & Growth Analysis Report, 20 …
The Canada IBD market is estimated to grow significantly at a CAGR of around 5.2% during the forecast period. Rising prevalence and incidence of IBD across the country is the major driving factor for the market. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per CCC, in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn’s disease,
Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031
Visiongain has published a new report on Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031: Forecasts by Drug Class (Biologics, Aminosalicylates, Corticosteroids, Antibiotics, Immunomodulators, Others), by Indication (Crohn’s Disease, Ulcerative Colitis), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading IBD Drug Companies AND COVID-19 Recovery Scenarios. Global Inflammatory Bowel Disease (IBD) drugs market was valued at US$ US$xx
US Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Forecast 20 …
The US IBD therapeutics market is estimated to grow significantly at a CAGR of around 4.7% during the forecast period. The factors such as the significant prevalence of IBD such as Crohn’s disease and ulcerative colitis across the country contributing to the market growth. As per the Centers for Disease Control and Prevention (CDC), the prevalence of Crohn’s disease and ulcerative colitis in the US was 201 and 238 per
France Inflammatory Bowel Disease (IBD) Therapeutics Market Size, Growth and For …
France IBD therapeutics market is estimated to grow significantly at a CAGR of around 4.6% during the forecast period. The growing IBD patient population is one of the major driving forces for the growth of the market in the country. According to the National Institutes of, Health, the total number of cases associated with Crohn's disease in France were registered to be around 72,522 in 2017. This signifies the opportunity
Global Inflammatory Bowel Disease (IBD) Therapeutics Market, Share, Trends & For …
The global IBD therapeutics market is estimated to grow significantly at a CAGR of around 5.0% during the forecast period. The rise in the number of IBD such as Crohn's disease and ulcerative colitis is augmenting the growth of the global IBD therapeutics market. The increasing prevalence of IBD results in the need for research for the treatment of IBD and innovations in healthcare systems to manage this complex and
Canada Inflammatory Bowel Disease (IBD) Market Share, Size & Forecast to 2025
The Canada IBD market is estimated to grow significantly at a CAGR of around 5.2% during the forecast period. Rising prevalence and incidence of IBD across the country is the major driving factor for the market. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per CCC, in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn's disease,